Is Antibe Therapeutics Inc. (ATBPF) a Buy, Sell, or Hold?
OTC : ATBPF
Antibe Therapeutics Inc.
$0.2156 USD
$0.0 (-0.19%)
- Volume
- 17.94K
- Average Volume
- 9.5K
- Market Capitalization
- $11.43M
- P/E Ratio
- -0.80
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.22
- Year Low
- $0.19
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $15.03
Company Overview
OTC
Daniel Marcel Legault
Medical - Devices
Healthcare
ATBPF
11
CA
USD
Liquidity Metrics
0.00
15.03
15.03
2.44
0.00
Sales & Valuation
-$
0.00
0.38
-0.96
-0.31
Profitability
-$0.37
-$19.48M
0.00%
0.00%
-40.16%
-27.60%
P/E Metrics
-0.80
-0.05
-0.05
Analyst Price Target & Rating
0/5
0 Analysts
%
Financial Health Scores
-3.83
1/9
$25.3M
$56.36M
$30.42M
-$18.25M
Key Metrics (TTM)
$8.88M
0.00
-0.46
15.03
-40.16%
-28.48%
-126.26%
-104.32%
0 days
Company Executives
| Name | Title |
|---|---|
| Scott Curtis | Vice President of Operations |
| Daniel Marcel Legault | President & Secretary |
Poll Results
No votes yet today — be the first to share your view!
About Antibe Therapeutics Inc. (OTC:ATBPF) Stock
Antibe Therapeutics Inc. is a biotechnology company focused on the innovation and development of novel therapeutic solutions and medical devices. The firm operates across Canada, Europe, the United States, and other international markets, concentrating its efforts on pain management, inflammation, and regenerative medicine. A key characteristic of its pharmaceutical products is their inherent design to prevent the gastrointestinal damage and bleeding frequently associated with non-steroidal anti-inflammatory drugs (NSAIDs). Its principal compound, Otenaproxesul, is a naproxen derivative engineered to release hydrogen sulfide, and it has successfully concluded a Phase 2B gastrointestinal safety study. This compound is being developed to address a range of conditions including post-operative ... pain, migraine, dysmenorrhea, traumatic injury, dental pain, and gout. Furthermore, the company is advancing ATB-352, a product currently in its preclinical stage, for the treatment of acute pain. Antibe Therapeutics Inc. was founded in 2009 and is headquartered in Toronto, Canada.
Frequently Asked Questions
-
What is the current Antibe Therapeutics Inc. (ATBPF) stock price?
-
Antibe Therapeutics Inc.(OTC:ATBPF) stock price is $0.2156 in the last trading session. During the trading session, ATBPF stock reached the peak price of $0.216 while $0.1889 was the lowest point it dropped to. The percentage change in ATBPF stock occurred in the recent session was --0.19% while the dollar amount for the price change in ATBPF stock was -$0.0.
-
ATBPF's industry and sector of operation?
-
The OTC listed ATBPF is part of Medical - Devices industry that operates in the broader Healthcare sector.
-
Who are the executives of ATBPF?
-
Scott Curtis | Vice President of Operations
Daniel Marcel Legault | President & Secretary
|
|
| -
How many employees does ATBPF have?
-
Number of ATBPF employees currently stands at 11. ATBPF operates from 15 Prince Arthur Avenue, Toronto, ON M5R 1B2, CA.
-
Link for ATBPF official website?
-
Official Website of ATBPF is: https://www.antibethera.com
-
How do I contact ATBPF?
-
ATBPF could be contacted at phone #None and can also be accessed through its website. ATBPF operates from 15 Prince Arthur Avenue, Toronto, ON M5R 1B2, CA.
-
How many shares of ATBPF are traded daily?
-
The average number of ATBPF shares traded daily for last 3 months was 9.5K.
-
What is the market cap of ATBPF currently?
-
The market value of ATBPF currently stands at $11.43M with its latest stock price at $0.2156